Samsung Biologics Signs Pharmaceutical Contract Manufacturing Agreement Worth 112.1 Billion KRW

[Asia Economy Reporter Lee Gwan-ju] Samsung Biologics announced on the 28th that it has signed a contract for contract manufacturing organization (CMO) with the global pharmaceutical company 'Eli Lilly Kinsale Limited.' The contract amount is approximately 112.13391 billion KRW.

The company stated, "The contract was initially signed on December 20, 2019, and the confirmed sales amount has increased due to the customer's increased demand," adding, "The confirmed contract amount may increase to 177.45 million USD through further negotiations with the customer."